Alexion Pharmaceuticals Inc.

NASDAQ:ALXN   3:59:59 PM EDT
115.17
-3.04 (-2.57%)
Products

Alexion Receives FDA Approval For New Advanced Formulation Of Ultomiris With Significantly Reduced Infusion Time

Published: 10/12/2020 12:46 GMT
Alexion Pharmaceuticals Inc (ALXN) - Alexion Receives FDA Approval for New Advanced Formulation of Ultomiris® (ravulizumab-cwvz) With Significantly Reduced Infusion Time.
Alexion Pharmaceuticals Inc - Plans to Make Ultomiris 100 Mg/ml Available Within a Few Days.
Alexion Pharmaceuticals Inc - Ultomiris 10 Mg/ml Will Continue to Be Available Until Mid-2021.
Alexion - Plan to Submit Regulatory Filings in U.S. & Eu in Q3 of 2021 for Ultomiris Subcutaneous Formulation and Device Combination for Pnh and Ahus.
Alexion Pharmaceuticals - Anticipate Receiving a Decision From European Commission for Ultomiris in November.